Piper Sandler Maintains Overweight on Tyra Biosciences, Raises Price Target to $56

Benzinga Newsdesk www.benzinga.com Positive 70.5%

Neg 0% Neu 0% Pos 70.5%

Piper Sandler analyst Allison Bratzel maintains Tyra Biosciences (NASDAQ:TYRA) with a Overweight and raises the price target from $42 to $56.